Drugs / VentriGel
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT02305602 | Sep 2015 → Sep 2018 | heart failure, myocardial infarction | Ventrix, Inc. | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2013-02-21 | Ventrix, Inc. | Results Ventrix's VentriGel™ Demonstrates Potential to Prevent Heart Failure Following Heart Attack ventrixbio.com ↗
Ventrix, Inc. announced today that its VentriGel cardiac repair scaffold safely and effectively mitigated left ventricular remodeling and improved cardiac function in pigs after myocardial infarction, or heart attack. |
All press releases naming this drug 2 releases
| Date | Issuer | Release |
|---|---|---|
| 2015-09-17 | Ventrix, Inc. | Ventrix Initiates Clinical Trial of VentriGel™ ventrixbio.com ↗ |
| 2013-02-21 | Ventrix, Inc. | Ventrix's VentriGel™ Demonstrates Potential to Prevent Heart Failure Following Heart Attack ventrixbio.com ↗ |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | VentriGel | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02305602 ↗ |
| Modality | Other / unclassified | “extracellular matrix hydrogel” NCT02305602 ↗ |
| Route | Other | “VentriGel delivered trans-endocardially” NCT02305602 ↗ |